Asunto(s)
COVID-19/terapia , Cuidados Críticos/organización & administración , Equidad en Salud/organización & administración , Pandemias/estadística & datos numéricos , Indicadores de Calidad de la Atención de Salud/organización & administración , Asignación de Recursos/organización & administración , Asignación de Recursos/estadística & datos numéricos , Anciano , Anciano de 80 o más Años , Cuidados Críticos/estadística & datos numéricos , Femenino , Equidad en Salud/estadística & datos numéricos , Humanos , Masculino , Persona de Mediana Edad , Indicadores de Calidad de la Atención de Salud/estadística & datos numéricos , SARS-CoV-2 , Estados UnidosRESUMEN
In this paper, we address how the COVID-19 pandemic has impacted informed consent for clinical research through examining experiences within Clinical and Translation Science Award (CTSA) institutions. We begin with a brief overview of informed consent and the challenges that existed prior to COVID-19. Then, we discuss how informed consent processes were modified or changed to address the pandemic, consider what lessons were learned, and present research and policy steps to prepare for future research and public health crises. The experiences and challenges for CTSA institutions offer an important perspective for examining what we have learned about informed consent and determining the next steps for improving the consent process.
RESUMEN
Clinical research is critical to combatting COVID-19, but regulatory requirements for human subjects protection may sometimes pose a challenge in pandemic circumstances. Although regulators have offered some helpful guidance for research during the pandemic, we identify further compliance challenges regarding institutional review board (IRB) review and approval, informed consent, emergency research, and research involving incarcerated people. Our proposals for regulatory flexibility in these areas seek to satisfy the goals of protecting participants and promoting the development of high-quality evidence to improve patient care. These recommendations may have relevance beyond the COVID-19 pandemic to enhance the efficiency of research oversight and participant protection more broadly.